Tezcat Biosciences, Inc.
Publicly observedNew Haven, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | New Haven | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Tezcat Biosciences, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | E6EJYYD5BJ23 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant18 Aug 2026Publicly observed
NIH SBIR/STTR award: Tumor-targeted delivery of radio/chemotherapy in pancreatic cancer.
USD 399,855.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Aug 2022Publicly observed
NIH SBIR/STTR award: A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.
USD 928,698.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Aug 2022Publicly observed
NIH SBIR/STTR award: A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.
USD 1,113,257.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant15 Jul 2020Publicly observed
NIH SBIR/STTR award: A novel monobody-drug conjugate to treat mutant Ras multiple myeloma
USD 205,593.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.